

**Encapsulated mitochondria to reprogram the metabolism of M2-type
macrophages for anti-tumor therapy**

Yonghui Wang^{1,2}; Chang Liu²; Xiaodong Ma²; Anne Filppula², Youbin Cui¹; Jiangbin Ye^{3*}; Hongbo Zhang^{1,2,4*}

¹Department of Thoracic Surgery, Organ Transplantation Center, The First Hospital of Jilin University, Changchun, China

²Pharmaceutical Sciences Laboratory, Åbo Akademi University, Turku 20520, Finland

³Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA.

⁴Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku 20520, Finland

*Corresponding Author

E-mail: hongbo.zhang@abo.fi; yejl@stanford.edu




Figure S1: TEM images of individual free mitochondria and ZIF-8 nanoparticles, and the morphology of free Mito under fluorescence microscope. (A): TEM image of isolated mitochondria; (B) TEM image of blank ZIF-8; (C): Brightfield image of free mitochondria; (D) Fluorescence image of free mitochondria.




Figure S2: Standard curve of ATP productive




Figure S3: Toxicity of pure ZiF-8 nanoparticles and results of M2Φ uptake with four groups. (A): Toxicity of blank ZiF-8 to 4T-1 cells and M2Φ; (B) Flow cytometric analysis of M2Φ uptake; (C) Uptake results of M2Φ after CellTracker™ CM-DiI membrane dye labeling (scale bar: 1 μm); (D) M2Φ uptake process of Mito@ZiF-8 under TEM.




Figure S4: Regulation of M2Φ Secretory Functions by Mito@ZiF-8. (A): Lysosome escapes of Mito@ZiF-8 at different time points (scale bar: 1 μm); (B): Mito@ZiF-8

regulated M2Φ secretion of CXCL 10 and IL-1β after 5 days incubation.




Figure S5: Differences in metabolic intermediates between Blank group and Mito group. (A) OPLS-DA analysis between Blank and Mito; (B) Volcano results between Blank and Mito; (C) Predictive analysis of metabolic models for Mito group; (D) The regulation of metabolic pathways in M2Φ after delivery to Mito was analyzed by bubble chart.




Figure S6: The structure of the Transwells model and the statistical results of cancer cell stemness. (A) Transwell model; (B) Statistics analysis of cancer stem cell population.